In the immediate neighbourhood of the almost 30-year-old GBA MDS headquarter, a state-of-the-art LEAN-optimized medical device testing laboratory has been developed over the last few months. With 2,700 m² of floor space, the laboratory area has quadrupled to over 1,600 m². As part of the GBA Group, GBA MDS utilizes state-of-the-art digital processes and cutting-edge laboratory equipment to increase the efficiency of its workflows and continue to optimally meet customer requirements for faster turnaround times.
The relocation of all key laboratory areas of GBA MDS has been successfully completed. A gradual move was chosen to ensure seamless support for our customers. The cell culture team successfully moved in the first week of July, after the microbiology team moved in June and the chemical analysis team moved in May. Below you will find first insights into the new location. Your known contacts are always available to schedule your next projects.
„We would like to thank the long-standing customers of GBA MDS for their continued trust, which has made this development possible in the first place. We are proud to be able to make the long-term commitment to short turnaround times, available capacities and the highest possible quality with our new location. We look forward to welcoming our customers to our new location - do not hesitate to contact us and convince yourself on site!“ say Dr. Timo Lebold and Felix Bunde, Managing Directors of GBA MDS.
Tests in accordance with DIN EN ISO/IEC 17025 will be carried out at the new location without interruption. GLP tests at the new location require an updated GLP certificate - this is expected to be issued on August 26, 2024 as a result of the inspection by the Bavarian supervisory authority. We will gladly schedule your GLP projects today so that they can be carried out immediately upon receipt of the updated GLP certificate. Microbiological tests (except hygiene monitoring) can still be carried out under GLP at the old location until the end of July.
About GBA MDS
GBA MDS is one of Europe's leading providers for the qualification and evaluation of medical devices. The portfolio includes laboratory analyses and other services in connection with the qualification of the biological compatibility of medical devices and their materials, the qualification of manufacturing, cleaning, packaging, sterilization processes and packaging systems as well as the validation of the reprocessing of medical devices.
The relocation of all key laboratory areas of GBA MDS has been successfully completed. A gradual move was chosen to ensure seamless support for our customers. The cell culture team successfully moved in the first week of July, after the microbiology team moved in June and the chemical analysis team moved in May. Below you will find first insights into the new location. Your known contacts are always available to schedule your next projects.
„We would like to thank the long-standing customers of GBA MDS for their continued trust, which has made this development possible in the first place. We are proud to be able to make the long-term commitment to short turnaround times, available capacities and the highest possible quality with our new location. We look forward to welcoming our customers to our new location - do not hesitate to contact us and convince yourself on site!“ say Dr. Timo Lebold and Felix Bunde, Managing Directors of GBA MDS.
Tests in accordance with DIN EN ISO/IEC 17025 will be carried out at the new location without interruption. GLP tests at the new location require an updated GLP certificate - this is expected to be issued on August 26, 2024 as a result of the inspection by the Bavarian supervisory authority. We will gladly schedule your GLP projects today so that they can be carried out immediately upon receipt of the updated GLP certificate. Microbiological tests (except hygiene monitoring) can still be carried out under GLP at the old location until the end of July.
About GBA MDS
GBA MDS is one of Europe's leading providers for the qualification and evaluation of medical devices. The portfolio includes laboratory analyses and other services in connection with the qualification of the biological compatibility of medical devices and their materials, the qualification of manufacturing, cleaning, packaging, sterilization processes and packaging systems as well as the validation of the reprocessing of medical devices.
